Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
PRX III Double Nickase Plasmid (h): sc-401730-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PRX III Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- PRX III Double Nickase Plasmid (h) and PRX III Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting PRDX3. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PRX III Antibody (1): sc-130336
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PRX III Double Nickase Plasmid (h) | sc-401730-NIC | 20 µg | $410.00 | |||
PRX III Double Nickase Plasmid (h2) | sc-401730-NIC-2 | 20 µg | $410.00 |
PRDX3 encodes peroxiredoxin III (PRX III), a mitochondria-localized thioredoxin-dependent peroxidase that reduces hydrogen peroxide and organic hydroperoxides to maintain redox homeostasis. By controlling mitochondrial ROS levels, PRX III influences oxidative phosphorylation efficiency, mitochondrial permeability, and redox-sensitive signaling pathways including apoptosis and stress-response networks. PRDX3 activity is linked to cellular adaptation to hypoxia and metabolic reprogramming, and altered expression has been associated with oxidative stress phenotypes observed across diverse cancers and neurodegenerative and inflammatory contexts. As a mitochondrial antioxidant node, PRX III is frequently studied for its impact on genome stability, proteostasis, and ROS-driven modulation of kinase and transcription factor activity.
PRX III Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the PRDX3 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within PRDX3. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt PRDX3 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of PRDX3-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.